ArticleJournal of virology1996
Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase.
Article in Journal of virology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 114 citations in OpenAlex.
- Adenovirus-mediated anti-AEG-1 ScFv expression driven by stathmin promoter inhibits tumor growth in cervical cancer.Cancer cell international · 2020Article
- Expression of Functional Anti-p24 scFv 183-H12-5C in HEK293T and Jurkat T Cells.Advanced pharmaceutical bulletin · 2017Article
- Capsid-Targeted Viral Inactivation: A Novel Tactic for Inhibiting Replication in Viral Infections.Viruses · 2016Review
- Bone Marrow Gene Therapy for HIV/AIDS.Viruses · 2015Review
- Engineering T Cells to Functionally Cure HIV-1 Infection.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Review
- A nucleic-acid hydrolyzing single chain antibody confers resistance to DNA virus infection in hela cells and C57BL/6 mice.PLoS pathogens · 2014Article
- Architecture and assembly of HIV integrase multimers in the absence of DNA substrates.The Journal of biological chemistry · 2013Article
- A protein ballet around the viral genome orchestrated by HIV-1 reverse transcriptase leads to an architectural switch: from nucleocapsid-condensed RNA to Vpr-bridged DNA.Virus research · 2013Article
- Zinc finger protein designed to target 2-long terminal repeat junctions interferes with human immunodeficiency virus integration.Human gene therapy · 2012Article
- Anti-CHMP5 single chain variable fragment antibody retrovirus infection induces programmed cell death of AML leukemic cells in vitro.Acta pharmacologica Sinica · 2012Article
- Article
- Architecture of a full-length retroviral integrase monomer and dimer, revealed by small angle X-ray scattering and chemical cross-linking.The Journal of biological chemistry · 2011Article
- HIV-1 IN inhibitors: 2010 update and perspectives.Current topics in medicinal chemistry · 2009Review
- Mode of inhibition of HIV-1 Integrase by a C-terminal domain-specific monoclonal antibody.Retrovirology · 2006Article
- Intracellular antibodies for proteomics.Journal of immunological methods · 2004Review
- Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides.Journal of virology · 2004Article
- Structural analyses of purified human immunodeficiency virus type 1 intracellular reverse transcription complexes.Journal of virology · 2003Article
- HIV-1 infection is facilitated in T cells by decreasing p56lck protein tyrosine kinase activity.Clinical and experimental immunology · 2003Article
- The production and application of single-chain antibody fragments.Folia microbiologica · 2003Review
- Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4.Gene therapy · 2001Article
Corrections and comments
- Commented on by
- Erratum issued
- Erratum issued
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Integration of viral DNA into a chromosome of the infected host cell is required for efficient replication of a retroviral genome, and this reaction is mediated by the virus-encoded enzyme integrase (IN). As IN plays a pivotal role in establishing infection during the early stages of the retroviral life cycle, it is an attractive target for therapeutic intervention. However, the lack of effective antiviral drug therapy against this enzyme has led to the testing of other novel approaches towards its inhibition. In these studies, a panel of anti-human immunodeficiency virus type 1 (anti-HIV-1) IN hybridomas has been used in the construction of single-chain variable antibody fragments (SFvs). The monoclonal antibodies produced by these hybridomas, and derived SFvs, bind to different domains within IN. We now demonstrate that intracellular expression of SFvs which bind to IN catalytic and carboxy-terminal domains results in resistance to productive HIV-1 infection. This inhibition of HIV-1 replication is observed with SFvs localized in either the cytoplasmic or nuclear compartment of the cell. The expression of anti-IN SFvs in human T-lymphocytic cells and peripheral blood mononuclear cells appears to specifically neutralize IN activity prior to integration and, thus, has an effect on the integration process itself. These data support our previous studies with an anti-HIV-1 reverse transcriptase SFv and demonstrate further that intracellularly expressed SFvs can gain access to viral proteins of the HIV-1 preintegration complex. This panel of anti-HIV-1 IN SFvs also provides the tools with which to dissect the molecular mechanism(s) directly involved in integration within HIV-1-infected cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.